Summary
The calcium channel blockers (calcium antagonists) have vasodilatory and cardiodepressant effects. These pharmacological properties explain, to a large extent, the antihypertensive, antianginal, and antiarrhythmic effects of these agents. Pharmacological differences between members of this class, e.g. differences in vascular selectivity, are well documented and can be exploited clinically.
The efficacy of calcium channel blockers in the prevention of cardiovascular events may depend on factors other than their vasodilatory and cardiodepressive effects. Much interest, for example, has been shown in their possible antiatherosclerotic effects. It is, however, at present not possible to ascertain how important these and other ancillary effects (such as plaque stabilisation) are for the putative cardioprotective effects of calcium channel blockers. There are, moreover, few in vitro or in vivo (animal or clinical) studies allowing valid comparison of the different calcium channel blockers with regard to these ancillary properties.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Materson B. Calcium channel blockers. Is it time to split the lump? Am J Hypertens 1995; 8: 325–9.
Vanhoutte P, Paoletti R. The WHO classification of calcium channel blockers. Trends Pharmacol Sci 1987; 81: 4–5.
Godfraind T. Cardioselectivity of calcium channel blockers. Cardiovasc Drugs Ther 1994; 8: 353–64.
Furberg C, Psaty B, Meyer J. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31.
Poole-Wilson P. 24-Hour protection and control: a new era of calcium antagonists. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: v–vi.
Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5.
Barnett A. FDA committee rules calcium-channel blockers safe. Lancet 1996; 347: 313.
Opie L, Messerli F. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995; 92: 1068–73.
Dzau V. Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994; 128: 1300–4.
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9.
Nayler WG. Amlodipine. Berlin: Springer-Verlag, 1993.
Waters D, Lespérance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am Heart J 1994; 128: 1309–16.
Lichtlen P, Hugenholtz P, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109–13.
Waters D, Lespérance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940–53.
Schroeder J, Gao S-Z, Alderman E, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328: 164–70.
Levine G, Keaney J, Vita J. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995; 332: 512–21.
Hillegass W, Ohman E, Leimberger J, et al. Ameta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol 1994; 73: 835–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bogaert, M.G. How Do Calcium Channel Blockers Prevent Cardiovascular Events. Drugs 52 (Suppl 4), 3–8 (1996). https://doi.org/10.2165/00003495-199600524-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199600524-00004